In Hyderabad, a six-year study has surfaced a quiet but consequential failure: men with breast cancer are arriving at hospitals months too late, their bodies already deep into a disease that medicine has long coded as belonging to women. The rarity of male breast cancer has paradoxically made it more dangerous, as both patients and clinicians struggle to recognize what they have not been taught to see. This is not merely a medical oversight — it is a story about how assumptions shape survival, and how silence, in the body and in public health, carries a mortal cost.
Male breast cancer patients in Hyderabad diagnosed at advanced stages due to diagnostic delays
Two patients died from disease progression; four patients abandoned follow-up care despite free treatment availability, indicating significant health and mortality impact.
Symptoms are often ignored or misinterpreted in men
Mark
Why does breast cancer in men get missed so often? It's the same disease.
Mimi
It's the same disease, but it's invisible in the cultural imagination. Doctors see a lump in a man's chest and their mind doesn't go there first. It goes somewhere else. That six-month delay isn't usually because of bad medicine—it's because no one is thinking to look.
Mark
But surely men notice something is wrong. They must feel it.
Mimi
They do. They feel the lump, the skin changes. But then they might not mention it, or they mention it casually, and the doctor doesn't take it seriously. There's no public messaging telling men to watch for these signs. All the awareness campaigns are aimed at women. A man with breast cancer is often as surprised as his doctor.
Mark
The study mentions stigma. What kind of stigma?
Mimi
The stigma of having a disease coded as female. Some men may feel embarrassed to seek care or to talk about it. Others may delay because they don't believe it's possible. By the time they arrive at a hospital, the cancer has had months to spread.
Mark
What about the patients who stopped coming back, even though treatment was free?
Mimi
That's the real tragedy. Free treatment isn't enough if you live far away, if you have no one to help you get there, if you're exhausted and isolated. The disease becomes not just medical but social—a burden too heavy to carry alone.
Mark
Is there hope in what Telangana is doing?
Mimi
There's a beginning. Making cancer notifiable means the government will finally have real numbers. But numbers alone don't save lives. You need doctors trained to see it, campaigns that speak to men, and a health system that doesn't treat male breast cancer as an afterthought.
O Pulso
- Nearly nine in ten male breast cancer patients in Hyderabad reach hospital at stage III or IV, meaning the window for easier treatment has already closed by the time anyone looks.
- An average six-month gap between a man noticing symptoms and receiving a diagnosis points to a systemic failure — doctors dismissing lumps, patients not knowing to insist, and a medical culture that rarely imagines cancer in a male chest.
- Two men in the study died from disease progression, and four others quietly disappeared from follow-up care despite free treatment being available, revealing that the barriers are not only clinical but social — stigma, distance, and disbelief.
- Telangana's new cancer notification mandate and calls for national registries offer a structural foothold, but experts warn that data infrastructure alone cannot save men who do not yet know they are at risk.
- Oncologists are calling for male-specific awareness campaigns and clinical guidelines, arguing that a disease affecting less than one percent of breast cancer patients still demands its own public health voice.
In Hyderabad, a six-year study has surfaced a quiet but consequential failure: men with breast cancer are arriving at hospitals months too late, their bodies already deep into a disease that medicine has long coded as belonging to women. The rarity of male breast cancer has paradoxically made it more dangerous, as both patients and clinicians struggle to recognize what they have not been taught to see. This is not merely a medical oversight — it is a story about how assumptions shape survival, and how silence, in the body and in public health, carries a mortal cost.
In Hyderabad's hospitals, men are arriving too late. A six-year study at ESIC Medical College tracking fifteen male breast cancer patients found that 60 percent presented at stage III and 27 percent at stage IV — one in four already at the furthest point the disease can reach. On average, six months passed between a man first noticing something wrong and receiving a diagnosis.
Researchers point not to biology but to blindness. Diagnostic inertia — the tendency to dismiss symptoms in men because male breast cancer is so rare — means that lumps go unexamined, skin changes go unnamed, and nipple retraction is attributed to something else. Two patients in the study arrived with ulcerated tumors, evidence of progression that had gone uninterrupted for months or years. None had obvious risk factors that might have prompted earlier suspicion.
Dr. Gumdal Vishesh, head of oncology at ESIC, puts it plainly: rarity has become an excuse for inattention. He urges men with suspicious symptoms to seek evaluation without delay and calls for genetic testing among those diagnosed. By 2025, nine of the fifteen patients remained alive with controlled disease, but two had died from progression and four had stopped attending follow-up care entirely — not because treatment was unavailable, but because distance, stigma, and a fundamental lack of awareness kept them away.
Dr. Nivalika Rajamoni of Yashoda Hospitals identifies a structural gap: there are no male-specific guidelines for breast cancer detection, and public health messaging has so thoroughly framed the disease as a women's issue that men rarely see themselves in the warnings. Telangana's recent designation of cancer as a notifiable disease is a step toward better data, and experts are calling for national registries and targeted campaigns. But these are long-horizon solutions. The study's deeper finding is simpler and more urgent — that survival depends on someone, doctor or patient, learning to look.
In Hyderabad's hospitals, a quiet crisis is unfolding in the bodies of men who arrive too late. One in four male breast cancer patients in the city walks through the door already at stage IV—the furthest point the disease can reach—and nearly nine out of ten arrive with cancer so advanced that treatment options have already begun to narrow. A six-year study conducted at ESIC Medical College and Hospital in Sanathnagar, tracking fifteen male patients between 2019 and 2025, found that 60 percent presented at stage III and another 27 percent at stage IV. The numbers tell a story of systematic oversight: an average of six months passes between the moment a man notices something wrong and the moment a doctor finally names it as cancer.
The culprit, researchers found, is not biology but blindness. Doctors call it diagnostic inertia—the tendency to dismiss or misread symptoms in men because breast cancer in males is so rare that it barely registers in the medical imagination. A man feels a lump behind his nipple. His skin thickens. His nipple retracts inward. He mentions it to a doctor, who may not think to look closely, or who assumes it is something else entirely. Two patients in the study arrived with tumors so far gone that the skin had ulcerated, a sign of months or years of progression without intervention. None of these men had family histories of breast cancer or obvious risk factors—no hormone exposure, no radiation, no occupational hazards that might have raised a flag. The disease simply arrived, and the system failed to see it.
Dr. Gumdal Vishesh, head of medical and hemato-oncology at ESIC Medical College, frames the problem plainly: breast cancer is rare in men, but that rarity has become an excuse for inattention. "Symptoms are often ignored or misinterpreted," he said. He calls for men with suspicious lumps or skin changes to seek evaluation without delay, and for those diagnosed to undergo genetic testing to determine whether inherited mutations are at play. The message is clear—early detection is possible, but only if someone is looking.
The human toll emerged in the follow-up data. By 2025, nine of the fifteen patients—60 percent—remained alive with their disease controlled. Five had completed treatment. Two were on hormone therapy. Two others with stage IV cancer had achieved stable disease, a small victory in the face of advanced illness. But the study also recorded losses: two patients died from disease progression, their cancers advancing despite treatment. Four more patients, representing 27 percent of the cohort, simply stopped coming for follow-up care. This last figure is perhaps the most troubling, because these were not patients without access. ESIC provided free treatment. The barriers were elsewhere—long distances to travel, lack of family support, the weight of stigma, and a pervasive lack of awareness that breast cancer could happen to them at all.
Dr. Nivalika Rajamoni, a senior oncologist at Yashoda Hospitals, points to a structural absence: there are no male-specific guidelines for breast cancer detection or management. The disease is so thoroughly coded as a women's issue in public health messaging that men do not see themselves in the warnings. Awareness campaigns focus on women. Screening programs target women. When a man develops breast cancer, he is often the first to be surprised, and his doctor may not be far behind. Rajamoni calls for campaigns designed specifically for men, acknowledging that male breast cancer, though rare—less than 1 percent of all breast cancers—demands its own voice in public health.
There are small signs of movement. Telangana recently designated cancer as a notifiable disease, a step that should improve data collection and give health officials a clearer picture of who is getting sick and when. Experts are also calling for national cancer registries and policy interventions tailored to the realities of male breast cancer. But these are long-term solutions to a problem that is killing men today. The study from Hyderabad suggests that the path forward requires both clinical vigilance—doctors learning to see breast cancer in men—and cultural shift, a recognition that this disease does not belong only to women, and that silence and delay are not inevitable.
Citações Notáveis
Breast cancer is rare in men, but symptoms are often ignored or misinterpreted.— Dr. Gumdal Vishesh, head of medical and hemato-oncology at ESIC Medical College
There is an urgent need for awareness campaigns focused on men, as male breast cancer is often missing from public health messaging.— Dr. Nivalika Rajamoni, Senior Oncologist at Yashoda Hospitals
Quer a matéria completa?
Leia o original em Times of India ↗
Health & Medicine